Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World...

Area of Science:

• Pharmacology
• Cardiology
• Clinical Trials

Background:

• Dabigatran is a direct-acting oral anticoagulant for stroke prevention in atrial fibrillation.
• Current dosing is a fixed two-dose scheme, unlike warfarin's adjusted dosing.
• Dabigatran's efficacy and safety correlate with plasma concentrations, which are highly variable.

Purpose of the Study:

• To compare the performance of current dabigatran dosing regimens with alternative proposals.
• To identify an improved dabigatran dosing regimen for optimizing therapeutic plasma concentrations.
• To inform patient outcomes and future dabigatran development.

Main Methods:

• Utilized a population pharmacokinetic model from over 9,000 clinical trial patients.
• Performed simulations comparing label dosing to proposed doses and regimens.
• Assessed trough plasma levels within the 75-150 ng/mL therapeutic range across renal function from 15-250 mL/min.

Main Results:

• Dabigatran demonstrated superior stroke reduction and similar bleeding risk compared to warfarin in Phase III trials.
• Simulations identified an improved dosing regimen requiring five schedules based on renal function.
• The proposed regimen better achieves the target therapeutic plasma concentration range (75-150 ng/mL).

Conclusions:

• The current dabigatran dosing regimen may not be optimal for all patients.
• A refined, individualized dosing strategy based on renal function can enhance therapeutic concentration achievement.
• This approach holds potential for improving patient outcomes and guiding future drug development.